

Corrigenda

aCaMKII Autophosphorylation Controls the Establishment of Alcohol Drinking Behavior

Alanna C Easton, Walter Lucchesi, Anbarasu Lourdusamy, Bernd Lenz, Jalal Solati, Yulia Golub, Piotr Lewczuk, Cathy Fernandes, Sylvane Desrivieres, Ralph R Dawirs, Gunther H Moll, Johannes Kornhuber, Josef Frank, Per Hoffmann, Michael Soyka, Falk Kiefer, The GESGA Consortium, Gunter Schumann, K Peter Giese and Christian P Müller

Neuropsychopharmacology (2013) 38, 2735; doi:10.1038/npp.2013.188

Correction to: *Neuropsychopharmacology* (2013) **38**, 1636–1647; doi:10.1038/npp.2013.60

In this article, the following collaborators of The GESGA Consortium are being added to the byline: Jens Treutlein¹, Sven Cichon^{2,3,4,5}, Monika Ridinger⁶, Manuel Mattheisen^{2,7,8}, Stefan Herms^{2,3,5}, Norbert Wodarz⁶, Peter Zill⁹, Wolfgang Maier¹⁰, Rainald Mössner¹⁰, Wolfgang Gaebel¹¹, Norbert Dahmen¹², Norbert Scherbaum¹³, Christine Schmäl¹, Michael Steffens⁷, Susanne Lucae¹⁴, Marcus Ising¹⁵, Bertram Müller-Myhsok¹⁶, Markus M Nöthen^{2,3,17}, Karl Mann¹⁸, and Marcella Rietschel¹

¹Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Heidelberg, Germany; ²Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany; ³Institute of Human Genetics, University of Bonn, Bonn, Germany; ⁴Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany; ⁵Division of Medical Genetics, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Germany; ⁶Department of Psychiatry, University Medical Center Regensburg, University of Regensburg, Regensburg, Germany; ⁷Institute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, Bonn, Germany; ⁸Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA; ⁹Department of Psychiatry, University of Munich, Munich, Germany; ¹⁰Department of Psychiatry, University of Bonn,

Bonn, Germany; ¹¹Department of Psychiatry and Psychotherapy, University of Düsseldorf, Düsseldorf, Germany; ¹²Department of Psychiatry, University of Mainz, Mainz, Germany; ¹³Addiction Research Group at the Department of Psychiatry and Psychotherapy, LVR Hospital Essen, University of Duisburg-Essen, Essen, Germany; ¹⁴Department of Psychiatric Pharmacogenetics, Max-Planck-Institute of Psychiatry, Munich, Germany; ¹⁵Department of Molecular Psychology, Max-Planck-Institute of Psychiatry, Munich, Germany; ¹⁶Department of Statistical Genetics, Max-Planck-Institute of Psychiatry, Munich, Germany; ¹⁷German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ¹⁸Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Heidelberg, Germany.

FUNDING AND DISCLOSURE

MR has received compensation for advisory activities from Lundbeck. NW received funds by Lundbeck and D&A Pharma for taking part in multi-centre randomized trials. He received speaker's honoraria and travel funds from Janssen-Cilag and Essex Pharma. NS received honoraria as an advisory board member of Sanofi-Aventis and Reckitt-Benckiser. He received lecture honoraria from Janssen, Lundbeck and Reckitt Benckiser.